Nomura Securities Downgrades Macrocure Ltd (MCUR) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- US stocks set for lower open as Iran stalemate lifts oil, yields
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Macrocure Ltd. Provides Update on Futility Analysis for Phase III Clinical Trial of CureXcell(R) in Venous Leg Ulcers
August 19, 2015 6:40 PM EDTPETACH TIKVA, Israel, Aug. 19, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. ("Macrocure" or the "Company") (NASDAQ: MCUR), a clinical-stage biotechnology company focused on advancing its novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that a pre-specified, futility analysis conducted by the Data Safety Monitoring Board for CureXcell® the Company's lead product candidate in its Phase 3 pivotal clinical study (MC-105) for venous leg ulcers (VLU) determined that this study is not expected to meet its primary endpoint.
"While we are disappointed with the results of the VLU futility analysis, given the positive clinical... More
